Coming to terms with nonsteroidal anti-inflammatory drug gastropathy

Drugs

Volumn 72, Issue 7, 2012, Pages 873-879

  Roth, Sanford H ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Adverse drug reactions; Celecoxib; Diclofenac; Esomeprazole; Esomeprazolenaproxen; Famotidine; Gastrointestinal disorders; Histamine receptor antagonists; Ibuprofen; Ibuprofenfamotidine; Misoprostol; Musculoskeletal disorders; Naproxen

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DIMETHYL SULFOXIDE; ESOMEPRAZOLE; FAMOTIDINE; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2; VALDECOXIB;

ABDOMINAL BLEEDING; ACUTE HEART INFARCTION; APPLICATION SITE REACTION; CARDIOVASCULAR DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRY SKIN; DYSPEPSIA; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEART INFARCTION; HELICOBACTER PYLORI; HIP FRACTURE; HUMAN; HYPERSENSITIVITY; MAGNESIUM BLOOD LEVEL; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; OSTEOARTHRITIS; PEPTIC ULCER; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH DISEASE; THROMBOSIS; VISUAL ANALOG SCALE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; TIME FACTORS;

EID: 84860776081     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11633740-000000000-00000     Document Type: Review

References (54)

1. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it-can we stop it? Arch Intern Med 1986 Jun; 146 (6): 1075-6
2. Lanas A, Garcia-Tell G, Armada B, et al. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk of cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 2011 Apr 14; 9: 38
3. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med 1987 Dec; 147 (12): 2093-100
4. Sun DC, Roth SH, Mitchell CS, et al. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis 1974 May; 19 (5): 405-10
5. US FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Medical product safety information. COX-2 selective and non-selective nonsteroidal anti-inflammatory drugs NSAIDs [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm151410.htm [Accessed 2012 Feb 24]
6. Melo Gomes JA, Roth SH, Zeeh J, et al. Doubleblind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993 Dec; 52 (12): 881-5
7. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987 Nov; 82 (11): 1153-8
8. Coles LS, Fries JF, Kraines RG, et al. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983 May; 74 (5): 820-8
9. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987May; 28 (5): 527-32
10. MassóGonzález EL, Pastrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010 Jun; 62 (6): 1592-601
11. Richette P, Hilliquin P, Bertin P, et al. Comparison of general practitioners and rheumatologists' prescription patterns for patients with knee osteoarthritis. BMC Musculoskelet Disord 2011 Apr; 12: 72
12. Roth SH. Understanding the COX-2/NSAID dilemma. Drugs 2005; 65 (14): 1915-7
13. Roth SH. From peptic ulcer disease to NSAID gastropathy: an evolving nosology. Drugs Aging 1995 May; 6 (5): 358-67
14. Manguso F, Riccio E, de Nucci G, et al.s Helicobacter pylori infection in bleeding peptic ulcer patients after non-steroidal antiinflammatory drug consumption.World J Gastroenterol 2011 Oct 28; 17 (40): 4509-16
15. Chan FK, LeungWK. Peptic-ulcer disease. Lancet 2002 Sep 21; 360 (9337): 933-41
16. Najm WI. Peptic ulcer disease. Prim Care 2011 Sep; 38 (3): 383-94
17. Hernández-D́az S, Rodŕguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000 Jul 24; 160 (14): 2093-9
18. Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 2004 Jan-Feb; 11 (1): 17-25
19. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247-55
20. Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010 Jan; 77 (1): 6-12
21. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part II. OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008 Dec; 16 (12): 137-62
22. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012 April; 64 (4): 465-74
23. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 Dec; 62 (12): 1145-55
24. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011 May; 70 (5): 818-22
25. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57 (8): 1331-46
26. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthroplasty), 2008 [online]. Available from URL: http://www.aaos.org/research/guide lines/OAKguideline.pdf [Accessed 2011 Jul 26]
27. National Institute for Health and Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. NICE clinical guideline 59. London: NICE, 2008
28. Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005 Nov; 32 (11): 2218-24
29. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007 Jul; 5 (7): 818-28
30. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007 Nov; 50 (5): 470-9
31. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8
32. Sun SX, Lee KY, Bertram CT, et al. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 2007 Aug; 23 (8): 1859-66
33. PavlicevićI, KuzmanićM, Rumboldt M, et al. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008 Fall; 15 (3): e372-82
34. McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. Plos Med 2011 Sep; 8 (9): e1001098
35. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011 Jan 11; 342: c7086
36. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999 Dec; 21 (12): 2065-79
37. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007 May 12; 369 (9573): 1621-6
38. Ares JJ, Outt PE. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des 1998 Feb; 4 (1): 17-36
39. Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediaterelease esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011 Jun; 27 (6): 1243-53
40. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006 Dec 27; 296 (24): 2947-53
41. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 Aug 4; 353 (5): 487-97
42. Duexis (ibuprofen and famotidine) [package insert]. Hunt Valley (MD): Pharmaceutics International, Inc., 2011
43. Weinblatt ME, Genovese MC, Klivitz AJ, et al. Efficacy, safety and tolerability of HZT-501, including users of lowdose aspirin, a single-tablet combination of ibuprofenfamotidine: results of two phase 3 trials [abstract]. Arthritis Rheum 2010; 62 Suppl. 10: 945
44. Voltarengel (diclofenac sodium topical gel) 1% [package insert]. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2009
45. PENNSAID (diclofenac sodium topical solution) 1.5% w/w [package insert]. Hazelwood (MO): Mallinckrodt Inc., 2010 Jun
46. Moen MD. Topical diclofenac solution. Drugs 2009; 69 (18): 2621-32
47. Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010 Jan; 50 (1): 50-61
48. Hui X, Hewitt PG, Poblete N, et al. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res 1998 Oct; 15 (10): 1589-95
49. Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009 Jun; 143 (3): 238-45
50. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (PENNSAID) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004 Oct; 31 (10): 2002-12
51. Roth SH, Fuller P. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res 2011 Jun 3; 4: 159-67
52. Haroutiunian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med 2010 Apr; 11 (4): 535-49
53. Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol 2010 Jun; 37 (6): 1236-43
54. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004 Oct 11; 164: 2017-23